论文部分内容阅读
本文成功地建立了以合成的小分子肽与蛋白质交联的偶联物为免疫原，制备单克隆抗体（ｍＡｂ）的技术路线。选定ＳＣＦ受体特异性肽段进行人工合成，将其偶联于ＢＳＡ免疫动物，应用细胞融合技术制备了抗两肽段的杂交瘤细胞７株。ＥＬＩＳＡ法和免疫印迹结果显示，其分泌的ｍＡｂ特异性强，与偶联载体及多种多肽生长因子均无交叉反应。经ＡＰＡＡＰ法鉴定，抗胞内羧基端肽的ｍＡｂＳＢ３０４与ＳＣＦ受体表达细胞系ＨＥＬ有弱的阳性反应；免疫组化测定与胎儿皮肤基底层色素细胞及胃粘膜上皮细胞呈阳性反应，提示ｍＡｂＳＢ３０４可识别天然状态的ＳＣＦ受体。
This article has successfully established a synthetic small molecule peptide and protein cross-linked conjugate as the immunogen, preparation of monoclonal antibody (mAb) technology route. Selected SCF receptor-specific peptide for artificial synthesis, coupled to BSA-immunized animals, the application of cell fusion technology anti-two peptide hybridoma cells were prepared 7 strains. ELISA and Western blotting results showed that the secreted mAbs were highly specific and had no cross-reaction with the conjugate carrier and various polypeptide growth factors. According to APAAP method, mAbSB304antibody against C-terminal peptide had a weak positive reaction with SCF receptor expressing cell line HEL. Immunohistochemistry showed positive reaction with fetal skin pigment epithelial cells and gastric mucosa epithelial cells, suggesting that mAbSB304 Identify SCF receptors in their native state.